Futura Medical Share Discussion Threads

[lbo] 12/12/2022 11:17

Placebos can also be very harmful especially medical devices which have undergone no long term safety studies. And if they delay or divert people from more appropriate treatment. A CE mark only requires ‘meets the General Safety’ requirements of medical devices. And we have seen many medical devices have to be recalled for safety reeasons

[lbo] 12/12/2022 11:16

How many times have you repeatedly posted the same misleading post. Oral PDE5i drugs are the proven safe, effective and accepted first line therapy for ED according to people and organisations who are qualified to make those recommendations. A ramper who is only making subjective statements based on him owning shares in a placebo gel and not the objective evidence is not what the the accepted standard of medical practice by the wider medical profession. Other therapies including Med3000 have not been fully validated with adequately controlled studies. You have also deliberately and repeatedly misrepresented the side effects and risks of the recommended first line therapy. It has many years of objective data in millions of users supporting why it is still the recommended first line therapy. Unlike Med3000 which has only deficient data supporting its efficacy and very little and very short term safety data only in a very few number of users. Some of its impedance safety studies rely only on cadavers not real life people. Med3000 has been used on less then circa 400 people! While Viagra has been used on many millions. And even in those small tests Med3000 causes headaches, nausea and painful burning in men and women. So if Med3000 was used on millions it would cause terrible side effects and harm in thousands based on the percentages of side effects.



A Viagra study also showed using a placebo was also just as likely to harm you. It compared some 4,500 patients taking the drug to about 3,100 on placebo. So based on that study Med3000 even as a placebo is just as likely to harm you as viagra.



Its all in the American Urological Association [AUA] guidelines’

The therapies have not been validated

‘what we have as standard of care, which includes pills, injections, penile prosthesis, and vacuum devices that we know work. Other therapies have not been included in the standard of care yet’

The first line therapy recommended in the General practice guidelines on ED is oral PDE5I drugs. Which would be based on all the available objective evidence. It would not be based solely on a rampers subjective and unqualified personal view. Or if a person just own shares in a company with a placebo gel alternative and who may have a vested interest and biased opinion.



First-line therapy

For most men with ongoing confirmed ED, first-line treatment will be a phosphodiesterase-5 inhibitor (PDE5I).



Phosphodiesterase 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) are recommended as first-line therapy. With established safety profiles, these drugs are well tolerated and effective

GPC prescribing lead Dr Andrew Green:

'There is no doubt that sildenafil is a safe and effective drug’

[lbo] 12/12/2022 10:15

how does a company expect to enforce a patent on something that was clearly already described in research literature!?



‘The Company has conducted initial literature and in vitro based research that has shown the cooling from the evaporation of these specific combinations of solvents’



There is a risk that some claims will either be challenged in future (eg on the grounds of non-obviousness or existence of prior art) and/or that another technology may be employed to achieve a similar effect. The protracted development times mean the clock has been ticking on the original issued patents, reducing the protected commercial products




A smooth gel intended for alcohol soluble actives. Provides cooling effect upon application while leaving minimal residue




The cooling effect of a topically applied product can be evaluated using a validated handheld thermal imaging system. When the gel matrix is destroyed after application to the skin, the bound water and alcohol evaporates and a measurable cooling-effect results.

[broomrigg] 12/12/2022 07:32

Friday was our 9th consecutive BLUE day. Will today be the 10th?!Whatever happens this is amazing performance from FUM shares.....well done to all investors!Revenues not far off.....then watch them flyyyyy ;-)

[lbo] 11/12/2022 19:25

Its all based on a sham placebo medical device gel being ramped by scammers all over the internet making false claims they cannot substantiate!



Recent research has shown that the placebo effect is not only similar for medical devices to medical trials; it is considerably larger, the effect of a sham device is almost three times that of an oral placebo.



Placebo Treatment: Don't Eat It, Rub it!

indications to suggest that a topical placebo induces stronger effects than an oral one.



Administrative Law Judge Upholds FTC's Complaint that POM Deceptively Advertised Its Products

erectile dysfunction claims were false and unsubstantiated because the study on which the company relied did not show that POM Juice was any more effective than a placebo.




Odds estimates indicated the largest likelihood of placebo response occurred in men who were black, were younger than 45 years, had mild ED, and did not have diabetes. The likelihood of a placebo response decreased as ED duration increased. The frequency of common adverse events was similar between placebo responders and nonresponders



In subsequent clinical studies, a surprisingly high percentage of EDDM patients 10% to 20% claimed that the placebo "improved my erections," thus indicating a psychological basis for their ED.

[lbo] 11/12/2022 18:24

https://www.ftc.gov/sites/default/files/documents/cases/2008/01/080103qtrayseventhcircuitappealruling.pdfSelling brass as gold harms consumers independent of any effect on pain. Since the placebo effect can be obtained from sugar pills, charging $200 for a device that is repre- sented as a miracle cure but works no better than a dummy pill is a form of fraud. Thats not all. A placebo is necessary when scientists are searching for the marginal effect of a new drug or device, but once the study is over a reputable professional will recommend whatever works best.Medicine aims to do better than the placebo effect, which any medieval physician could achieve by draining off a little of the patients blood. If no one knows how to cure or ameliorate a given condition, then a placebo is the best thing going. Far better a placebo that causes no harm (the Q-Ray Ionized Bracelet is inert) than the sort of nostrums peddled from the back of a wagon 100 years ago and based on alcohol, opium, and wormwood. But if a condition responds to treatment, then selling a placebo as if it had therapeutic effect directly injures the con- sumer. See Kraft, Inc. v. FTC, 970 F.2d 311, 314 (7th Cir. 1992) (a statement violates the FTC Act ‘if it is likely to mislead consumers, acting reasonably under the cir- cumstances, in a material respecthttps://academic.oup.com/book/6511/chapter-abstract/150416159?redirectedFrom=fulltext&login=falseBias and FraudThere are numerous biases in medical research that render evidence from such research systematically misleading. Some of these biases are exacerbated by conflicts of interest, including fantastic financial incentives. The most important biases in medical research include confirmation bias, design bias, analysis bias, and publication bias. Arguably, some forms of bias, such as publication bias, should be considered as fraud. The pervasiveness of bias in medical research justifies one of the premises of the master argument for medical nihilism. Medical research is malleable due to the many biases, and such malleability allows for the production of evidence that suggests medical interventions are effective, whether or not they are in fact effective.https://help.magicapp.org/knowledgebase/articles/294932-how-to-rate-risk-of-bias-in-randomized-controlledWhat method-issues to consider when assessing Risk of BiasConcealment of randomizationThose enrolling patients are aware of the group (or period in a cross-over trial) to which the next enrolled patient will be allocated (major problem inpseudo or quasi randomized trials with allocation by day of week, birth date, chart number etc.)BlindingPatient, caregivers, those recording outcomes, those adjudicating outcomes, or data analysts are aware of the arm to which patients are allocated (or the medication currently being received in a cross-over trial)Loss to follow-upLoss to follow-up and failure to adhere to the intention to treat principle in superiority trials; or, in non-inferiority trials, loss to follow-up and failure to conduct both analyses considering only those who adhered to treatment, and all patients for whom outcome data are availableSelective outcome reportingIncomplete or absent reporting of some outcomes and not others on the basis of the resultsUse of unvalidated outcome measures (e.g., patient-reported outcomes)Considerations in the design of clinical trials for erectile dysfunctionhttps://www.openaccessjournals.com/articles/considerations-in-the-design-of-clinical-trials-for-erectile-dysfunction.pdfThe use of randomized controlled trials (RCTs) that are double-blinded and placebo-controlled is no doubt the optimum design for addressing clinical questions in ED and of paramount importance being the systematic and standardized approaches in the stages of design in order to avoid undesirable bias.